H3B-6527

H3B-6527 is a potent and orally active FGFR4 inhibitor with potential antineoplastic activity. Upon administration, H3B-6527 specifically binds to and blocks FGFR4. This prevents the activation of FGFR4, inhibits FGFR4-mediated signaling and leads to an inhibition of cell proliferation in FGFR4-overexpressing tumor cells.


Cat. No.: EX-A1510	Purity: >98%

	Chemical structure of H3B-6527

For research only, Do not use for Human!

Size	Unit Price (US$)	Stock
50mg	485	In-stock
100mg	785	In-stock
200mg	1250	In-stock

Send PO to E-mail:order@excenen.com; or Fax:+86 020 81619670

Discount Request


CAS No.	1702259-66-2
Purity	>98%
Formula	C29H34Cl2N8O4
Mol Weight	629.537
Appearance	solid powder
Solubility	Soluble in DMSO
Shelf Life	>2 years if stored properly
Storage	Powder -20℃ 2 years; In solvent -20℃ 1 month;
Shipping	Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Reference:	[1]. Repana, D., et al. Targeting FGF19/FGFR4 Pathway: A Novel Therapeutic Strategy for Hepatocellular Carcinoma. Diseases 2015, 3, 294-305. [2]. Joshi, J.J., et al. H3B-6527 is a potent and selective inhibitor of FGFR4 in FGF19-driven hepatocellular carcinoma. Cancer Res. 77(24), 6999-7013 (2017).
CoA	CoA of H3B-6527

Smiles:	CCN1CCN(CC1)C1=CC(NC(=O)C=C)=C(NC2=CC(=NC=N2)N(C)C(=O)NC2=C(Cl)C(OC)=CC(OC)=C2Cl)C=C1


		Search